Approval · Notice of Compliance 21026 · 2018
AG-GABAPENTIN: Notice of Compliance 21026
Issued June 27, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21026
- Date
- June 27, 2018
- Company
- Angita Pharma Inc.Boucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Canadian reference product
- NEURONTIN (Pfizer Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AG-GABAPENTIN | 02477912 | Dormant |
| AG-GABAPENTIN | 02477920 | Dormant |
| AG-GABAPENTIN | 02477939 | Dormant |
Medicinal ingredients
- GABAPENTIN 100 MG per TAB
- GABAPENTIN 300 MG per TAB
- GABAPENTIN 400 MG per TAB